BMY vs CMCSA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMY Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bristol-Myers Squibb Co. (BMY) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CMCSA counters with relative strength in Valuation. Fundamentally, BMY trades at 8.8x Forward P/E with 32.4% operating margin (+6.9% YoY revenue) versus CMCSA at 7.1x Forward P/E and 14.7% operating margin (-6.1% YoY). In options structure, BMY sits in CONSOLIDATION (24th %ile IV; Dealer Gamma Walls on Pro) against CMCSA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMY Revenue | CMCSA Revenue | BMY Op. Margin | CMCSA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $22.6B | $94.5B | 21.8% | 20.1% | BMY |
| FY2019 | $26.1B | $108.9B | 13.2% | 19.4% | CMCSA |
| FY2020 | $42.5B | $103.6B | -21.2% | 16.9% | CMCSA |
| FY2021 | $46.4B | $116.4B | 15.1% | 17.9% | CMCSA |
| FY2022 | $46.2B | $121.4B | 13.7% | 11.6% | BMY |
| FY2023 | $45.0B | $121.6B | 17.8% | 19.2% | CMCSA |
| FY2024 | $48.3B | $123.7B | -18.5% | 18.8% | CMCSA |
| FY2025 | $48.2B | $123.7B | 14.6% | 16.7% | CMCSA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BMY | CMCSA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $119.3B | $88.3B | Larger Scale | BMY |
| Trailing P/E Ratio Valuation | 12.9x | 7.9x | Lower Multiple | CMCSA |
| Forward P/E Ratio Valuation | 8.8x | 7.1x | Lower Multiple | CMCSA |
| Revenue Growth (YoY) Growth | +6.9% | -6.1% | Higher Growth | BMY |
| Operating Margin (TTM) Profitability | 32.4% | 14.7% | Higher Margin | BMY |
| Net Profit Margin Profitability | 18.5% | 9.2% | Higher Margin | BMY |
| Return on Equity (ROE) Capital Efficiency | 44.0% | 11.4% | Higher ROE | BMY |
| 52-Week Range Position Momentum | 58% ($45โ$69) | 36% ($20โ$33) | Stronger Trend | BMY |
| Beta / 30D Volatility Risk Regime | 0.16ฮฒ ยท 28% Vol | -0.01ฮฒ ยท 32% Vol | Lower Realized Risk | BMY |
| Unified Institutional Score Composite Signal | 48.9 / 100 (HOLD) | 32.8 / 100 (SELL) | Higher Composite | BMY |